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ABSTRACT 
 
Solzak, Jeffrey Peter, M.S., Purdue University, August 2012. Molecular and 
Cellular Mechanisms Leading to Similar Phenotypes in Down and Fetal Alcohol 
Syndromes. Major Professor: Randall J. Roper. 
 
 
 
Down syndrome (DS) and Fetal Alcohol Syndrome (FAS) are two leading 
causes of birth defects with phenotypes ranging from cognitive impairment to 
craniofacial abnormalities. While DS originates from the trisomy of human 
chromosome 21 and FAS from prenatal alcohol consumption, many of the 
defining characteristics for these two disorders are stunningly similar. A survey of 
the literature revealed over 20 similar craniofacial and structural deficits in both 
human and mouse models of DS and FAS. We hypothesized that the similar 
phenotypes observed are caused by disruptions in common molecular or cellular 
pathways during development. To test our hypothesis, we examined 
morphometric, genetic, and cellular phenotypes during development of our DS 
and FAS mouse models at embryonic days 9.5-10.5. Our preliminary evidence 
indicates that during early development, dysregulation of Dyrk1a and Rcan1, 
cardinal genes affecting craniofacial and neurological precursors of DS, are also 
dysregulated in embryonic FAS models. Furthermore, Caspase 3 was also found 
to have similar expression in DS and FAS craniofacial neural crest derived
ix 
 
tissues such as the first branchial arch (BA1) and regions of the brain. This may 
explain a developmental deficit by means of apoptosis. We have also 
investigated the expression of pAkt, a protein shown to be affected in FAS 
models, in cells located within the craniofacial precursor of Ts65Dn. Recent 
research shows that Ttc3, a gene that is triplicated and shown to be 
overexpressed in the BA1 and neural tube of Ts65Dn, targets pAkt in the nucleus 
affecting important transcription factors regulating cell cycle and cell survival. 
While Akt has been shown to play a role in neuronal development, we 
hypothesize that it also affects similar cellular properties in craniofacial 
precursors during development. By comparing common genotypes and 
phenotypes of DS and FAS we may provide common mechanisms to target for 
potential treatments of both disorders.  
One of the least understood phenotypes of DS is their deficient immune 
system. Many individuals with DS have varying serious illnesses ranging from 
coeliac disease to respiratory infections that are a direct result of this 
immunodeficiency. Proteasomes are an integral part of a competent and efficient 
immune system. It has been observed that mice lacking immunoproteasomes 
present deficiencies in providing MHC class I peptides, proteins essential in 
identifying infections. A gene, Psmg1 (Dscr2), triplicated in both humans and in 
Ts65Dn mice, is known to act as a proteasome assembly chaperone for the 20S 
proteasome. We hypothesized that a dysregulation in this gene promotes a 
proteasome assembly aberration, impacting the efficiency of the DS immune 
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system. To test this hypothesis we performed western blot analysis on specific 
precursor and processed β-subunits of the 20S proteasome in thymic tissue of 
adult Ts65Dn. While the β-subunits tested displayed no significant differences 
between trisomic and euploid mice we have provided further insight to the origins 
of immunodeficiency in DS. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction to Down Syndrome and Fetal Alcohol Syndrome 
Down syndrome (DS) is the most common genetic disorder that affects 
approximately 1 out of 750 live births mostly occurring from three copies of 
chromosome 21 (Hsa21). This chromosomal aberration was first described by 
Jerome Lejeune in 1959 while conducting research in attempts to cure DS; 
however many of the distinct phenotypes associated with DS were first defined 
by John Langdon Down in 1866. DS can occur several different ways with the 
vast majority (~95%) caused by non-disjunction resulting in a true trisomy 
(HASSOLD and SHERMAN 2000). Approximately 5% of all other DS cases are 
caused by Robertsonian translocations, mosaicicm, or partial trisomy of Hsa21. 
Robertsonian translocations in DS are a result of a hybrid chromosome 
containing the long arm of Hsa21 and usually the long arm of Hsa14 (BEREND et 
al. 2003). Mosaicisim, the rarest of DS occurrences, is where only a portion of 
the cells contain a true trisomic nature. These individuals have a tendency to 
have less severe phenotypes associated with DS and many times go unnoticed.  
DS has been defined by over 80 distinct phenotypes that affect 
craniofacial characteristics, heart, central nervous system, immune system, and
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skeletal structure (BLAZEK et al. 2011; EPSTEIN 2001; RICHTSMEIER et al. 2000; 
VAN CLEVE and COHEN 2006). Characteristics developing later in life may include 
immunodeficiency, early onset Alzheimer disease, and celiac disease (EPSTEIN 
2001; RAM and CHINEN 2011). Many of these traits however vary widely from 
individual to individual (WISEMAN et al. 2009). Even though the genetic nature of 
DS has been identified, the mechanisms and pathways that influence these 
phenotypes are still largely unknown. 
Fetal alcohol syndrome (FAS) is a disorder that is caused by the 
consumption of alcohol by the expectant mother. It affects approximately 1 out of 
1000 live births (ABEL and HANNIGAN 1995). This particular disorder has been 
observed for centuries but it was not until 1973 that two Seattle physicians fully 
described and brought attention to FAS (JONES and SMITH 1973). Since their 
publication, concern for FAS has become much more abundant going as far as 
charging a woman who drank during her pregnancy with felony child abuse in 
1991(ARMSTRONG and ABEL 2000).  
Many individuals that have FAS present variations of phenotypes as well 
as severity. This may be due to genetic variation as well as quantity and length of 
exposure to ethanol during development (ANTHONY et al. 2010a; CHEN et al. 
2011). Many of these phenotypes are much like those found in DS and include 
craniofacial deficits, abnormalities in neurogenesis, and other structural 
anomalies (ANTHONY et al. 2010a; GRESSENS et al. 1992; RILEY et al. 2011). 
Because of the wide range and variation of phenotypes, it is difficult to diagnose 
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FAS early in life (SCHAEFER and DEERE 2011). These phenotypes arise in 
development and do not progress in adults. However, due to the damage already 
done, many individuals with FAS face many behavioral problems and cognitive 
impairment throughout their lives (FOLTRAN et al. 2011; JACOBSON et al. 2011; 
WYPER and RASMUSSEN 2011).  
  
1.2 Mouse models of DS and FAS 
Many investigators of DS and FAS use mouse models to emulate traits of 
these disorders found in humans. While there are several types of mice 
exhibiting DS like phenotypes, the Ts65Dn mouse model has been most often 
used with great success. The genes on Hsa21 are mostly conserved in mice; 
however these genes are separated across three different chromosomes, 10, 16, 
and 17. Chromosome 16 (Mmu16) in mice contains many of the significant 
genes, as well as the majority of the DS orthologues found in humans. Ts65Dn 
contains a trisomic segment of Mmu16 which accounts for approximately half of 
the gene orthologues that are triplicated in human DS (GARDINER et al. 2003). 
The aneuploidy of this mouse causes similar phenotypes as seen in humans 
such as reduced mandible and maxillary regions, rostro-caudal dimensions of the 
neurocranium, and overall reduction and flattening of the face (RICHTSMEIER et al. 
2000). 
FAS investigators have several mouse model resources to study. It has 
been observed that embryos from different genetic backgrounds vary in 
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susceptibility to ethanol consumption while also presenting different resultant 
phenotypes. For this reason, the mouse strain C57BL/6 is the top choice 
because of its willingness to consume ethanol and the craniofacial features 
created are the closest to traits found in human FAS (ANTHONY et al. 2010a; 
KHISTI et al. 2006; OGAWA et al. 2005; SULIK 2005). Investigators also use a 
culturing method when studying development. Instead of feeding the mother 
ethanol, the embryos are extracted at a specific time point and placed in an 
ethanol solution. While culturing embryos may cause differences of expression in 
specific genes, it is an invaluable way to control the developmental age and 
amount of ethanol the embryo receives (CHEN et al. 2011). 
 
1.3 Phenotypes of DS and FAS 
 
1.3.1 Morphogenic Traits 
Anthropometry is the science of measuring the size, weight, or proportions 
of an organism’s body. It has been largely used to compare the differences in 
humans with DS and FAS to normal individuals as well as the mouse models for 
these respective syndromes (ANTHONY et al. 2010a; RICHTSMEIER et al. 2000; 
RICHTSMEIER and DELEON 2009). Many of these measurements have focused on 
their defining craniofacial abnormalities. Through measurements using DS and 
FAS models, investigators found many specific deficits in facial height, width, and 
depth, as well as smaller orbital regions, nasal length, and ear distances 
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(ALLANSON et al. 1993; ANTHONY et al. 2010a; MOORE et al. 2002; MOORE et al. 
2007; RICHTSMEIER et al. 2000). Other measurements have concentrated on 
regions of the brain in which deficits have been observed. Areas such as the 
hippocampus, cerebellum, and cortex have been shown to be significantly below 
normal size in both syndromes (CEBOLLA et al. 2009; FIDLER and NADEL 2007; 
LOMOIO et al. 2009; NORMAN et al. 2009; SERVAIS et al. 2007). Using these 
measurements, regions of interest have been elucidated for molecular and 
cellular research.  
 
1.3.2 Implications of Neural Crest in Development 
The neural crest (NC) is a multipotent stem cell population that emerges 
and migrates from the neural folds to produce many important tissues throughout 
development. Once they arrive to their destination, NC can differentiate into a 
number of different cells. The more specific cranial neural crest (CNC) have the 
potential to differentiate into cells of the nervous system, bone, and connective 
tissue (SANTAGATI and RIJLI 2003). The CNC makes up the vast majority of the 
cell population in the first branchial arch (BA1), a region which gives rise to the 
mid and lower face including the mandible. For this reason, the BA1 is largely 
investigated in craniofacial diseases such as DS and FAS. In addition to the 
mandible, other NC derived structures display deficits as well, including the heart 
and GI tract (AWAN et al. 2004b; BURD et al. 2007; HOFER and BURD 2009; 
WEIJERMAN et al. 2010). Ts65Dn mice display NC deficits resulting in craniofacial 
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and neurological abnormalities (ROPER et al. 2009). This NC deficit may be 
caused by the dysfunction of several integral genes that can be tied to the 
trisomic nature of DS. In FAS, tissues contain deficits caused by an early and an 
above normal occurrence of apoptosis where large amounts of NC reside (WANG 
and BIEBERICH 2010).  
 
1.3.3 Genetic Expression of Cardinal Genes 
Of the approximately 300 genes that are triplicated in DS, there are 
several that have been studied extensively. Dyrk1a is a serine-threonine kinase 
that is found on Hsa21 and is triplicated in most of the major DS mouse models 
including Ts65Dn. It is an important kinase that regulates many downstream 
proteins and transcription factors. Some of these transcription factors include 
cyclic AMP response element-binding protein (CREB), forkhead in 
rhabdomyosarcoma (FKHR), and nuclear factor of activated T cells (NFAT) 
(ARRON et al. 2006; BRANCHI et al. 2004). Dyrk1a dysregulation affects many 
functions such as proliferation, differentiation, and cell survival (YABUT et al. 
2010). Because of the multiple roles regulated by Dyrk1a, it has been implicated 
in many traits of which neurodegenerative diseases are the most studied (JONES 
et al. 2012; WEGIEL et al. 2011a). Dyrk1a has been shown to have a role in 
Alzheimer disease (AD), seen early in DS individuals, by hyperphosphorylating 
tau causing impaired microtubule assembly and neurofibrillary degeneration 
(RYOO et al. 2008; WEGIEL et al. 2011b). The phosphorylation of APP by an 
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overexpressed Dyrk1a is also thought to be a main cause of the pathogenesis of 
AD (RYOO et al. 2008). DS individuals have also presented amyloid senile 
plaques associated with AD symptoms (PARK et al. 2009a). The associated 
mechanism is an interaction between beta-amyloid precursor protein (APP) and 
Dyrk1a (PARK et al. 2007). With APP’s location on Hsa21, the expression levels 
are increased allowing this to occur.  
Regulator of calcineurin 1 (Rcan1 or Dscr1) is another gene that has been 
implicated in several phenotypes in DS. This is done through the increase of 
Rcan1 and its inhibition of calcineurin, a calcium activated serine/threonine 
protein phosphatase (FUENTES et al. 2000). When calcineurin is inhibited, 
proteins and transcription factors are not dephosphorylated affecting their 
activity. Rcan1 plays several roles and is expressed in many tissues in 
development including the central nervous system. In adults, Rcan1 has been 
shown to be expressed in several tissues such as the heart, liver, and many 
important regions of the brain including the cerebral cortex and hippocampus 
(ERMAK et al. 2001). It has been implicated in the development of Alzheimer 
disease by inhibiting the dephosphorylation of tau (LLORET et al. 2011). Rcan1 
has also been known to play roles in cardiac and skeletal muscle hypertrophy as 
well as immunodeficiency through its interaction with Nfat (HARRIS et al. 2005; 
RAM and CHINEN 2011).  
Dyrk1a and Rcan1 have significant interactions with Nfat, an important 
transcription factor hypothesized to be involved in DS. With a theoretical 
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increased dosage, both Dyrk1a and Rcan1 may play an inhibitory role on Nfat 
keeping it from localizing in the nucleus (EPSTEIN 2006). Nfat has been linked to 
bone development with a role in osteoblast and osteoclast differentiation and 
homeostasis (ASAGIRI et al. 2005; FROMIGUE et al. 2010; LEE et al. 2009). It also 
has been investigated as a potential mediator of apoptosis during development, 
being integral in neurogenesis, and a potential cause of craniofacial 
abnormalities, cognitive impairment, and motor function (ARRON et al. 2006; 
SRIVASTAVA et al. 1999). 
 
1.3.4 Occurrence of Apoptosis 
Apoptosis has been a common theme in investigating developmental 
deficits in individuals with DS and FAS. Although actual mechanisms are still 
under debate, it has been shown that there is nearly a five-fold increase in 
apoptosis in the BA1 of embryos treated with ethanol (WANG and BIEBERICH 
2010). More specific investigation shows that in developing embryos of several 
different FAS models, ethanol causes high levels of apoptosis in NC (FLENTKE et 
al. 2011; GARIC-STANKOVIC et al. 2005; WANG and BIEBERICH 2010). Other studies 
show that an epigenetic mechanism, like methylation, may have an effect on pro 
apoptotic genes in FAS models (LIU et al. 2009). Apoptosis has also been 
studied in DS, however unlike FAS, adult models have had more of a focus. It 
has been shown that there is a common occurrence of early onset Alzheimer 
disease accompanied by apoptosis in regions of the brain in individuals with DS 
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(LU et al. 2011). Recent studies confirm an overabundance of apoptosis located 
in the cerebellum that may be caused by trisomic genes such as Rcan1 (SUN et 
al. 2011). Ets2, a gene triplicated in DS, has also been shown to be induced by 
oxidative stress and has the potential to cause overstimulated proapoptotic 
pathways in both DS and Alzheimer (HELGUERA et al. 2005).Currently there have 
been studies focusing on apoptosis in DS neural development as well. A recent 
study found that an increase of S100B, a trisomic gene, may result in apoptosis 
and oxidative stress in human neural progenitors (LU et al. 2011). There have 
been no investigations to study the possible expression or effects of high 
occurrence of apoptosis in craniofacial precursors and a possible cause of 
distinct DS phenotypes. 
 
1.3.5 Expression of Activated Akt in DS and FAS 
 Understanding the mechanisms behind the craniofacial and neurological 
deficits of DS remains integral in current research. While Dyrk1a and Rcan1 have 
been implicated in both facial and neuronal traits, there are many other genes 
such as Ets2, Olig1, and Olig2 that are suspected as well (CHAKRABARTI et al. 
2010; HELGUERA et al. 2005; LU et al. 2011). While several genes may play an 
essential role in the development of these traits, little is known about how much 
of a role each one has and the underlying pathways involved.  
 In recent studies, a novel gene that is triplicated in both Ts65Dn and 
humans with DS that affects neurogenesis when it is expressed at increased 
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levels has been identified (BERTO et al. 2007). This gene, Ttc3, is an E3 ligase 
that targets Akt for ubiquitination when it is activated (SUIZU et al. 2009). Akt is a 
serine/threonine kinase that is responsible for many processes including cell 
proliferation, cell migration, cell survival, and differentiation (ENOMOTO et al. 2005; 
PENG et al. 2003; SHIOJIMA and WALSH 2002; SUIZU et al. 2009; WANG and 
BRATTAIN 2006). It does this by its ability to act on specific transcription factors 
such as CREB and NF-κB (PATRA et al. 2004; WANG and BRATTAIN 2006). For 
these reasons, it has been highly investigated in several types of cancer as a 
potential for pharmacotherapy. It has also been observed as a crucial gene in 
Proteus syndrome, a genetic disorder in which a hyperactive PI3K-Akt pathway 
causes abnormal bone calcification, overgrowth of skin, brain, connective tissue, 
and tumor susceptibility (LINDHURST et al. 2011). Another protein Akt regulates is 
p300, a transcriptional coactivatior. When Akt is activated via phosphorylation 
and is localized in the nucleus, it binds to p300 which then increases histone 
acetyl transferase activity (HAT) (HUANG and CHEN 2005). With HAT activity 
increased, transcription factors are able to access DNA that was previously 
blocked. This also opens DNA access for other proteins such as polymerases to 
induce transcription. 
While pAkt and Ttc3 have been observed to be dysregulated in DS in vitro 
models, a recent genomic analysis of FAS has shown that Akt is downregulated 
(HARD et al. 2005). Unlike DS, individuals with FAS have decreased inactive form 
of Akt due to an increase in PTEN, a protein responsible for the inhibition of the 
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PI3K-Akt cascade (GREEN et al. 2007; XU et al. 2003). With Akt being profoundly 
involved in cell survival and the signaling pathway of apoptosis, it is reasonable 
to assume that apoptosis found in FAS models may be caused by a deficiency of 
Akt in the BA1. 
 
1.4 Immunodeficiency in Down syndrome 
Individuals with DS have been shown for over 30 years to have a 
decreased functional immune system (BURGIO et al. 1978). There are many traits 
that have been investigated in DS, however, immunodeficiency is one of the least 
understood. Diseases such as acute lymphoblastic leukemia, hypothyroidism, 
and coeliac disease are major problems in individuals with DS (BIRGER and 
IZRAELI 2012; GEORGE et al. 1996; SELIKOWITZ 1993). Two of the more abundant 
problems are respiratory and ear infections. Many of these infections may be 
caused by morphological traits such as abnormal inner ear canal and 
tracheomalacia (RAM and CHINEN 2011). While these are thought to be 
secondary, much of the initial problem lies in the mechanisms that control the 
immune system. Many of these mechanisms including proteasomal activity, 
which plays a major role in the immune system, may be regulated by genes that 
are triplicated in DS. 
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1.4.1 Proteasomes and immunodeficiency 
The 26S eukaryotic proteasome is made up of two sections, a catalytic 
20S proteasome and a 19S regulatory particle (SASAKI et al. 2010). The 20S 
proteasome is made up of numerous α and β subunits creating a cylindrical 
structure. While many recent studies have focused on how this structure is 
assembled, it is known that there are proteins responsible for helping assemble 
the proteasomes. One of these helper proteins is called the proteasome 
assembly chaperone 1 (PAC1). Its responsibility lies in the accurate assembly of 
the 20S proteasome and in particular dealing with the α subunits. This process 
using PAC 1 has been shown to be essential in specific tissues of the developing 
mouse including the brain (SASAKI et al. 2010).  
Proteasomes are an integral part in sustaining the immune system. They 
play an important role of removing invading proteins from the cell and slicing 
them up into pieces via the ubiquitin system. These pieces are then used in 
creating the peptides used in MHC class I molecule binding. This is the basis for 
the vertebrate adaptive immunity (KASAHARA et al. 2004). There are two major 
categories of proteasomes, the standard proteasome and the 
immunoproteasome. The immunoproteasome is the one thought to be specific to 
create these MHC class I binding peptides (MURATA et al. 2008). Within the 
immunoproteasome category, a more specific proteasome named the 
thymoproteasome has been discovered recently. 
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 The thymoproteasome is distinct in that the β5 subunit is different from 
the standard and immunoproteasome. The β5t, the “t” standing for thymus, 
contains a different configuration in which contains a distinct make-up different 
than β5i and β5 (FLOREA et al. 2010). This difference in composition creates a 
different peptidase activity compared to other β5 subunits. This type of activity 
can be characterized by the amino acids present in the S1 pocket of the β5 
subunit. Compared to the other two known β5 subunits, β5t contains more 
hydrophilic residues creating a weaker chymotrypsin-like peptidase activity 
(MURATA et al. 2007). This weaker chymotrypsin-like activity presents a decrease 
in the Michaelis constant values, however, the overall activity of the proteasome 
was not changed. It is thought that this difference on protein degrading activity 
caused by β5t gives rise to specialized peptides, utilized in positive selection of 
CD8+ T cells (MURATA et al. 2008).  
 
1.5 Hypotheses 
 
1.5.1 Similarities in DS and FAS 
Individuals with DS and FAS have been observed to present similar 
morphological phenotypes. For this reason we hypothesize that the Ts65Dn 
mouse model of DS exhibits analogous craniofacial phenotypes to an FAS 
mouse model and these phenotypes arise from similar molecular and cellular 
origin. We examined craniofacial characteristics of our DS and FAS mouse 
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models by performing microCT scans to confirm previous studies. Molecular 
comparisons were analyzed by observing the expression of Dyrk1a and Rcan1, 
genes of interest in DS, in three embryonic regions of DS and FAS models. We 
also examined the apoptotic expression in the Ts65Dn at E10 to analyze the 
patterning as compared to FAS data at similar developmental points. We show 
that mouse models of DS and FAS exhibit similar molecular and cellular patterns 
in the craniofacial precursor suggesting a common origin to the abnormal 
craniofacial development. 
 
1.5.2 pAkt in DS and FAS 
The activated form of Akt is exceedingly important in the development of 
all vertebrates. It is responsible for the regulation of several key transcription 
factors and proteins involved in an array of cellular processes. Several studies 
have shown that this protein plays a major role in tissue development, specifically 
the brain. We hypothesize that pAkt expression is decreased in both DS and FAS 
in the brain causing neuronal deficits and in the craniofacial precursors resulting 
in proliferation and cell survival shortfalls. These abnormalities are hypothetically 
caused by the increased expression of the E3 ligase Ttc3 in DS and 
dysregulated PTEN in FAS resulting from ethanol exposure. While both of these 
syndromes have different origins of how pAkt is affected, the deficits caused by 
cellular abnormalities will help support the similar craniofacial and neurological 
abnormalities observed in individuals with DS and FAS.  
15 
 
 
1.5.3 Proteasome assembly in Ts65Dn 
Immunodeficiency is a characteristic in DS that is not well understood. Upon 
finding a gene that is triplicated in both humans and DS mouse models 
responsible for proteasome assembly we hypothesize that Psmg1 (Dscr2), a 
proteasome assembly chaperone, is affected in DS individuals. This 
dysregulation may cause a decreased number of thymoproteasomes in DS, 
which can be shown by the levels of precursor versus mature β5t subunits in 
Ts65Dn. With a decrease in thymoproteasomes, an insufficient library of novel 
MHC class I binding peptides may be present resulting in the immunodeficiency 
phenotypes observed in DS. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Breeding of mouse model embryos of DS and FAS 
  Female B6EiC3Sn a/A-Ts(1716)65Dn (Ts65Dn), female B6.129S4-
Gt(ROSA)26Sortm1Sor/J (B6.R26R), and C3H/HeJ (C3H) mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME). B6(R26R)C3F1 mice were bred 
by crossing B6.R26R females with C3H males (BLAZEK et al. 2011). Ts65Dn E10 
embryos were generated by crossing Ts65Dn females with Wnt1-LacZ males. 
Establishment of embryonic age started at midnight after breeding and plugs 
were found. E10 embryos were isolated by euthanizing the mother 10 days after 
plugging. 
FAS in vitro model embryos were taken at E8 by euthanizing C57BL/6 
dams (Harlan, Inc., Indianapolis, IN) with CO2. The uterus of the dam was placed 
in 0.1 M PBS at 37º C. Embryos were dissected out of the tissue and placed in 
PBS containing 4% fetal bovine serum. Three embryos with 3-6 somites were 
placed into 20 mL culture bottle containing 70% heat-activated rat serum and 
30% PB1 buffer. Culture bottles were gassed with air like consistency of 20% O2, 
5% CO2, and 75% N2. After preculture period, alcohol exposure consisting of 
moving the embryos to a medium containing 6 µl/ml of 95% ethanol solution. 
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Embryos were treated for 44 hours (OGAWA et al. 2005). FAS in vivo models 
were generated by treating C57BL/6J dams from E7 to E16 with 4.8% alcohol. 
2.2 Polymerase Chain Reaction (PCR) Genotyping 
DNA was isolated from toes cut from mice approximately 7-10 days old, 
born to Ts65Dn dams. Toes were subjected to Proteinase-K (Bioline, Taunton, 
MA) and T:E:N:S (50 mM Tris pH 7.5, 100mM EDTA pH 8.0, 400 mM NaCl, 0.5% 
sodium dodecyl sulfate) overnight in a 55º C water bath. Using NaCl, toes were 
salted out, centrifuged at 13,000 rpm, and precipitated using 95% and 70% 
ethanol respectively. 50 µl H2O was added and samples were allowed to remain 
at room temperature for at least two hours before storage at 4º C. 
Original PCR genotyping was performed using gene probes for a single 
nucleotide polymorphism within the Zdhhc14 gene on mouse chromosome 17 
(Mmu17). Using forward (AAATAGTAGCATCTCATGAGTG) and reverse 
(GCTTCTCTAAGATGCACTATG) primers (Invitrogen), the triplication could be 
observed due to DBA/2J allele near the breakpoint of Mmu1716 caused by 
reciprocal translocation from C57BL/6J and C3H/HeJ strains. After PCR, a Sac I 
restriction digest was applied to convert the normal product of 246 bp into two 
bands of 175 bp and 71 bp. If the trisomic allele was present, the digest would 
continue to work on normal parental alleles while also showing an uncut 246 bp 
band. This produced either two bands for positive or one band for negative as the 
71 bp band was unable to be seen on agarose gels. This PCR genotyping was 
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not 100% accurate. FISH was used to confirm Ts65Dn positive pups. (LORENZI et 
al. 2010) 
Current PCR genotyping utilizes probes found on either side of Mmu1716 
breakpoint. Probes consisting of Mmu17 forward 
(GTGGCAAGAGACTCAAATTCAAC) and Mmu16 reverse 
(TGGCTTATTATTATCAGGGCATTT) were used along with forward 
(TGTCTGAAGGGCAATGACTG) and reverse (GCTGATCCGTGGCATCTATT) 
control probes. These two sets of probes provide a 275 bp and 544 bp bands 
respectively. Ts65Dn positive mice exhibit two bands while negative have one. 
FISH was not needed to confirm these results. (REINHOLDT et al. 2011)  
 
2.3 Fluorescence In Situ Hybridization (FISH) Genotyping 
Yolk sacs from embryos were placed in 1.5 mL microcentrifuge tube with 
0.5 mL Dulbecco’s PBS (DPBS, Mediatech, Inc., Manassas, VA). Collagenase 
(Type Xl-s, Sigma-Aldrich Corp., St. Louis, MO) was placed into 37º C water bath 
to thaw and warm. Yolk sacs were centrifuged for 1 minute at 12,000 rpm and 
the supernatant was removed. They were resuspended in 0.5 mL DPBS, 
vortexed, and centrifuged again for 1 minute at 12,000 rpm. The supernatant was 
removed and 0.5 mL of collagenase was added to each tube. They were 
resuspended and incubated for 30 minutes in the 37º C water bath. The tubes 
were centrifuged for 1 minute at 12,000 rpm, the supernatant removed, and 0.5 
mL 0.075 M KCl was added. They were vortexed and incubated for 30 minutes 
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more at 37º C. A 3:1 solution of methanol and water was made during the 
incubation. At the end of the incubation, one drop of the 3:1 fix was added and 
the tubes were vortexed. They were centrifuged for 1 minute at 12,000 rpm and 
the supernatant was removed. The pellets were resuspended in 0.5 mL of 3:1 fix 
making sure that the pellet is dislodged from the bottom of the tube. The samples 
were stored at 4º C for 24 hours but not more than one week (MOORE et al. 
1999). 
Slides were labeled, creating two slides per sample. Tubes containing 
samples were centrifuged for 5 minutes at 12,000 rpm and all but 100 µL of 3:1 
(methanol:acetic acid) fix was removed. A single drop of distilled H2O was placed 
on each slide. The pellet was resuspended with a clean pipet and using the 
“dropping” technique, the cells were put evenly on each of the two slides. The 
slides were placed over a beaker of boiling water for approximately one minute to 
fix the cells, were washed with 3:1 fix, and dried overnight at room temperature. 
To hybridize, the slides were incubated for 30 minutes at 37º C in saline-
sodium citrate (SSC). At this time, humidified boxes were placed in 37º C 
incubator to warm and Denhyb (Insistus Biotechnologies, Albuquerque, NM) and 
probe were allowed to reach room temperature in the dark. Once Denhyb has 
reached room temperature, it was vortexed and 10:1 Denhyb / probe solution 
was made allowing for 20 percent more for each slide. The solution was warmed 
in 37º C water bath. Three coplin jars were filled with 70%, 85%, and 100% 
ethanol and placed into 4º freezer. The slides were placed into these jars 
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respectively for two minutes each. The rest of the procedure was done in a 
darkened room. Two dry baths were warmed to 37º C and 85º C. Each slide was 
dried and allowed to warm for 3 minutes on 37º C dry bath along with Denhyb / 
probe solution. Each slide had 7 µL of solution placed on cells, coverslips placed 
over cells, sealed with rubber cement, and placed on 85º C dry bath for 5 
minutes. Slides were placed into preheated humidified box overnight. 
For wash and detection of the cells, rubber cement and coverslips were 
removed and slides were washed in SSC preheated to 68-70º C for 5 minutes. 
Slides were placed into room temperature SSC for 7 minutes and 8 µL of room 
temperature Antifade / DAPI (Millipore, Billerica, MA) was placed onto cells. 
Coverslips were immediately put on and put into slide book. Slides were viewed 
shortly after for maximum results using a fluorescent microscope. A minimum of 
10 cells were counted looking for two or three marker chromosomes showing 
negative and positive trisomic cells respectively. 
 
2.4 Gene expression analysis of Ts65Dn and Ethanol exposed mouse models 
For Ts65Dn embryos, pregnant mothers were euthanized at E10 and the 
embryos were extracted. Somite age, approximately 24-28 somites, was 
matched to FAS mouse model counterparts. FISH was performed as previously 
described on Ts65Dn yolk sac DNA to identify those exhibiting trisomic marker 
chromosomes. Both embryonic models were dissected into three parts including 
the head, the BA1, and the remaining body. RNA was isolated from these three 
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fragments using PureLink RNA micro kit (Life Technologies, Grand Island, NY) 
and following manufacturer’s instructions. RNA was converted to cDNA using 
Taqman reverse transcription assay reagents (Applied Biosystems, Foster City, 
CA). Real-Time PCR was performed using target (Dyrk1a and Rcan1) and 
endogenous (Ipo8) gene probes (Applied Biosystems, Foster City, CA). Ipo8 was 
used as the non-dysregulated option for the endogenous gene upon finding out 
that Gapdh was dysregulated in the FAS mouse model. Procedure followed 
manufacturer’s instructions (TaqMan Gene Expression Assay, Applied 
Biosystems, Foster City, CA) 
 
2.5 MicroCT 
Ts65Dn models were anesthetized using isoflurane (Vedco Inc., St. 
Joseph, MO) in an induction chamber. While sedated, the mice were dissected 
open, exposing the heart. Using a 25 gauge needle, 40 mL of 4% 
paraformaldehyde (PFA) was injected into the left ventricle. Immediately after 
filling the heart to capacity, the right atrium was cut to allow blood to drain. At this 
time a blood sample was taken for FISH genotyping. All 40 mL was used until the 
lungs had turned white indicating all of the blood had been replaced. The 
circulatory system was then flushed with 40 mL of cold 1X PBS. The mice were 
decapitated and the heads stored in 4% PFA at 4ºC until microCT scan.  
FAS embryos were treated with 4.8% ethanol from E7 to E16. FAS scans 
took place on anethesized mice and was initiated in an induction chamber with 
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isoflurane levels at 1.5% and 0.8-1.2 liter/min, and maintained at 0.5 liter/min 
during the 45 minutes scans. Both model scans were performed at postnatal day 
21 (p21). All microCT images were acquired with 50 kVp and isotropic 46 µm 
resolution using EVS-R9 system (GE Healthcare, Waukesha, WI) at the Indiana 
University School of Medicine. 
 
2.6 Immunohistochemistry 
Both DS and FAS embryo models, once cultivated, were placed in 4% 
PFA for a minimum of 2 days. One experimental and control embryo were placed 
in a 10% gelatin mold which was allowed to harden at and placed in 4% PFA at 
4º C for a minimum 2 days. These molds were then trimmed and sectioned on a 
vibratome (Leica Biosystems Inc., Richmond, IL) at 40 µm. Sections were placed 
in a vial with 0.1 M PBS for storage. The sections were washed initially with 0.1 
M PBS and treated for 10 minutes in 3% H2O2. Once washed again in PBS, they 
were exposed to 1% Triton X-100 overnight. The next day, the sections were 
washed again and blocked in Goat kit buffer (0.1% Triton X-100 and 1.5% normal 
goat serum in 0.1 M PBS) for 90 minutes on a shaker. Cleaved caspase-3 (Cell 
Signaling Technology, Boston, MA) was used as a primary antibody at 1:150 
dilution and incubated overnight. Washed again in PBS, the sections were 
incubated for 90 minutes in biotin conjugated goat anti-rabbit secondary antibody 
at 1:500 dilution (Jackson ImmunoResearch, West Grove, PA). Yet another wash 
in PBS, the sections were then incubated for another 90 minutes in peroxidase-
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conjugated streptavidin using 1:500 dilution (Jackson ImmunoResearch, West 
Grove, PA). The sections were then washed in PBS six times and in 0.05M TBS 
four times. Incubation of the sections was done in 0.05% Diaminobenzidine 
(DAB, Sigma-Aldrich, St. Louis, MO) in 0.05 M TBS with an additional 10-15 
minutes of 0.003% H2O2 added. Sections were washed four times in 0.05M TBS 
and six times in 0.1 M PBS. Once the sections were placed on slides, they were 
dried overnight. They were Nissl counterstained with methyl green to show 
contrast of the c-caspase-3 stain (CHEN et al. 2011). 
 
2.7 Protein Homogenization from adult tissue 
Homogenization buffer was created using 150 mM NaCl, 20 mM Tris-HCl, 
0.2% NP40, 1.0% protease inhibiting cocktail, and Millipore water added to 10 
mL. The buffer solution was chilled by placing on ice for >10 minutes. To 
homogenize, appropriate sized tissue was placed in labeled 1.5 mL centrifuge 
tubes. 400 mL of cold homogenization buffer was placed into the tubes 
containing the tissue and promptly homogenized with a motorized mortar and 
pestle. Tissue was spun in centrifuge for 15 minutes, 13,000 rpm, and 4º C. 
Being careful to not take pellet at the bottom or the lipid layer at the top, 200 mL 
was taken out of spun homogenization. The protein solution was put into another 
tube and spun again for 10 minutes under same conditions. In the same fashion 
100 mL was taken out, placed into new tubes, and was immediately placed on 
ice. 
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2.8 BCA protein concentration assay 
Protein concentration was evaluated using the Bicinchoninic acid (BCA) 
technique. The assay solution used was made up of BCA solution A and Solution 
B (ThermoFisher Scientific, Waltham, MA) at 50:1 respectively. All samples 
tested had 1.0 mL added to each cuvette. For controls; 35.0, 42.5, 46.2, and 48.1 
µL of homogenization buffer was added to samples with 50 µL of buffer added to 
blank. To those controls; 15, 7.5, 3.75, and 1.88 µL of BSA protein was added 
respectively to samples to have a total of 50 µL of sample with the assay 
solution. For each tissue sample, 5 µl was added to 45 µL of homogenization 
buffer along with the 1.0 mL of assay solution in each cuvette. The control 
samples were then placed into the spectrometer (BioMate 3S, ThermoFisher 
Scientific, Waltham, MA) and absorbance was measured at 562 nm. The tissue 
samples were then placed and measured in the same fashion. Using the 
absorbance and µg of BSA protein in each solution, a graph was created. Using 
line of best fit and creating an equation using Microsoft Excel, tissue sample 
protein concentration was formulated. The amount of µg in each sample was 
divided by 5 to get a final number of µg/µL. Samples for loading were created 
based upon these final numbers. 20 µg of protein was calculated and added to 
Millipore H2O to have a final volume of 20 µL. To the protein and H2O, 4 µL of 5x 
Laemmli loading buffer was added. The samples were boiled for three minutes, 
allowed to cool, and loaded into polyacrylamide gels. 
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2.9 Polyacrylamide Gel Electrophoresis 
Loading plates were cleaned as to be sure that there was no dirt or dust 
that would ruin the gel. The 1.0 mm plates were placed into the holder for loading 
of the gels. Two gels were used, a 12% running gel and a 4% stacking gel. 5mL 
of running gel was created using 1.41 mL diH2O, 1.25 mL resolving buffer (1.5 M 
Tris-HCl pH 8.8), 1.46 mL 40% polyacrylamide (Bio-Rad Laboratories, Inc. 
Hercules, CA), 0.8 mL bisacrylamide (Bis) (Bio-Rad Laboratories, Inc.), 25 µL 
20% SDS (Sigma-Aldrich, St. Louis, MO), 5 µL Tetramethlyethylenediamine 
(TEMED, Sigma-Aldrich), and 50 µL 10% Ammonium Persulfate (APS, Sigma-
Aldrich) was added when gel was ready to load into plates. The solution was 
added to the plates to approximately 1.0 cm below the top of the plates. 
Immediately isopropanol was added to ensure that the top of the gel was 
covered. While the gel is setting, the stacking gel was created using 1.74 mL 
diH2O, 312.5 µL 8x stacking buffer (1 M Tris-HCl pH 6.8), 241.5 µL 
polyacrylamide, 166.5 µL Bis, 12.5 µL 20%SDS, 2.5 µL TEMED, and 25 µL of 
10% APS when gel is ready to be loaded. Once the running buffer was set, the 
isopropanol was absorbed using filter paper, rinsed with water and absorbed with 
filter paper again. The stacking buffer was loaded into the plates to the top and 
the 1.0 mm comb for the gel was placed into the plates, ensuring that there are 
no bubbles. Once the gel has been set, approximately 10-15 minutes, the comb 
was removed and the wells of the gel rinsed with distilled water. The gel was 
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placed into the gel apparatus and running buffer was filled to the designated line 
according to manufacturer’s directions (Bio-Rad Laboratories, Hercules, CA). 
Each PAGE was run at 80 volts (v), 400 milliamps for 20-30 minutes until protein 
has migrated past the stacking gel. The voltage was increased to 120 v for 
approximately 1-1.5 hours until dye migrated out of the gel. 
 
2.10 Western Blot 
The SDS-PAGE gel was taken out of the gel apparatus and soaked in 
trans-buffer solution. Six pieces of filter paper, three for each side, was cut to the 
size of the gel. PVDF membrane was also cut to the same size. The PVDF was 
soaked in methanol to ensure absorption of tris-glycine transfer buffer. The PVDF 
was taken out of the methanol and soaked in tris-glycine buffer. The filter paper 
was placed in the tris-glycine buffer as well. A sandwich was created with three 
pieces of filter paper on the bottom, the PVDF membrane next, the SDS-PAGE 
gel, and then the final three pieces of filter paper. This sandwich was placed in a 
Bio-Rad Transfer cell with the PVDF membrane below the SDS-PAGE gel. The 
power source was run at 15 v, 0.9 A, and 30 W for a duration of 25 minutes. The 
transfer was found to be successful if the bands from the ladder were seen on 
the PVDF membrane. 
In a tray, the PVDF membrane was soaked in a 1X TBS solution to rinse 
the salts for five minutes. The TBS was poured off and 10 mL of 5% (w/v) non-fat 
milk powder solution in 1X TBS was poured over the membrane. This was 
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allowed to block the membrane overnight at 4º C. After incubation, the blocking 
buffer was poured off and primary was added at 1:1000 dilution for β5t antibody 
(Enzo Life Sciences, Inc., Farmingdale, NY) and was incubated at room 
temperature for 60 minutes. The membrane was then washed three times for five 
minutes each in 1X TBS with 0.1% Tween 20 (Sigma-Aldrich, St. Louis, MO).The 
secondary was added using TBS-Tween at a dilution of 1:4000 and was 
incubated for another hour at room temperature. The membrane was washed 
again another three times for five minutes using TBS-Tween. 
For exposure, the membrane was taken out of the wash and placed into 
new tray. The detection solution, 1.0 mL, was added to the membrane for 1.5-2 
minutes ensuring that the whole membrane was covered. The solution was then 
allowed to run off and the membrane was placed into a sleeve making sure no 
bubbles were present. This was then taped into the film cassette and exposed in 
the dark room for 30 seconds, 45 seconds, one minute, and two minutes. Film 
was then developed and scanned for analysis. 
 
2.11 Cryostat embedding and sectioning 
Embryos were dissected from Ts65Dn positive dams and yolk sac DNA 
was isolated for genotyping. Embryos were fixed in 4% paraformaldehyde, 5% 
sucrose in 0.1M phosphate buffer (pH 7.4) for 90 minutes. Embryos were rinsed 
in 1X PBS two times for 10 minutes. Infiltration of the embryos was allowed to 
take place overnight in 20% sucrose in 0.1 M phosphate buffer.  
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Before embedding a 3:1 mixture of the 20% phosphate buffer solution and 
Tissue-Tek OCT embedding compound (Sakura Finetek USA, Inc., Torrance, 
CA) was allowed to sit for 20 minutes while dry ice was obtained. Molds were 
filled halfway with OCT mixture, placed into tray with a dry ice-70% EtOH 
mixture, and embryos were oriented using a dissecting microscope. The mold 
was then filled and allowed to freeze in the dry ice. Embryo molds were stored at 
-80º C. Before cryostat sectioning, molds were placed into -20º C freezer for one 
hour. 
 
2.12 Immunofluorescence 
The slides were removed from -80º C freezer and allowed to come to 
room temperature. The slides were washed in 1X PBS for 10 minutes. For 
permeablization, slides were washed with gentle shaking in 1X PBS with 0.5% 
Triton X-100 for 15 minutes. They were then exposed to antigen retrieval in 1X 
PBS with 1% SDS for 5 minutes. The slides were washed in 1X PBS with 
0.2%Triton X-100 three times for 5 minutes making sure all SDS was removed. 
Sections on the slides were circled with PAP pen to create a hydrophobic barrier 
and promptly placed into humidified chamber for 20 minutes to prevent sections 
from drying out. Tissues were blocked with goat blocking buffer (5% normal goat 
serum, 0.025% Triton X-100, in 1X PBS) for 60 minutes at room temperature. 
The blocking buffer was carefully removed and primary antibody for pAkt (Cell 
Signaling) was added, 1:200 dilution factor in blocking buffer, and placed in 
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humidified chamber at 4º C overnight. The next day the slides were taken out of 
the fridge and allowed to come to room temperature. Excess antibody was 
carefully removed and slides were washed two times for 10 minutes in 1X PBS 
with 0.2% Triton X-100 at room temperature. In a dark room, the appropriate 
Alexa-fluor secondary antibody (Invitrogen) was applied at 1:1000 dilution in PBS 
with 0.2% Triton X-100 and incubated for 60 minutes. Excess antibody was 
removed and slides were washed 10 minutes each in PBS Triton X-100 and 
PBS. Pro gold Dapi/Antifade (Life Technologies, Grand Island, NY) mounting 
media was added and coverslips were applied. Each side of the coverslip was 
sealed using clear nail polish and allowed to dry. Slides were stored at 4º C in the 
dark until pictures could be taken using Olympus FV-111-MPE confocal 
multiphoton microscope (Olympus, Center Valley, PA). 
 
2.13 Immunofluorescence Analysis 
Comparison of tissues was performed by using similar embryonic cross 
sections which were found by observing tissues present in each section. After 
immunostaining, using the sections, tissues were qualitatively analyzed for 
differences. This was performed by utilizing ImageJ (National Institute of Health, 
Bethesda, MD). The pAkt image had the background intensity subtracted by 
using the Math function. The amount of background that was subtracted stayed 
the same throughout all pictures, 200, to restrict any bias. The nuclei picture was 
then selected and threshold was established. Once again, the threshold number 
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remained the same, 500, throughout the analysis to restrict bias. The nuclei 
picture was then divided by the value of 255 to remove any background. Using 
the image calculator, the pAkt image was multiplied by the nuclei picture giving 
fluorescent expression only in the nucleus. Using the measuring tool, the mean 
intensity was gathered from the multiplied picture and the pAkt picture. The final 
step was to divide the fluorescence found in the nuclei by the total found for pAkt. 
This number gave the percent fluorescence in the nuclei alone. After the analysis 
was complete, a summary was produced. The fluorescence value and standard 
deviations were recorded and plotted in Excel. 
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CHAPTER 3: RESULTS 
 
3.1 Craniofacial analysis of DS and FAS 
 Because craniofacial deficits are observed in both DS and FAS, we 
examined previously published literature to identify precise anthropometric 
measurements for comparison. Approximately twenty craniofacial 
measurements, including facial depth, canthal distances, nasal length, and 
maxillary and mandibular arc, were found that corresponded to DS and FAS in 
both human and mouse models (Table 1). All of the measurements were 
observed to be similar with only one measurement, the minimal frontal breadth, 
differing between DS and FAS mouse models. With the tremendous amount of 
similarity of craniofacial measurements, other physiological traits were 
investigated including the brain, heart, and other organs and structures. The 
brain presented many of the same deficits in both DS and FAS including an 
abnormal dentate gyrus in the hippocampus, reduced number of Purkinje cells in 
the cerebellum, reduction of cerebellar size, and overall neuronal impairment of 
the cortex. The heart, kidneys and gastrointestinal (GI) tract all displayed similar 
morphological irregularities including septal defects in the heart and 
pseudoobstructions of the GI tract. Observing similarities in over 30 unique 
measurements and characteristics between DS and FAS, we hypothesized that
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Ts65Dn and ethanol treated FAS mice would also display these similar 
characteristics. To achieve this, microCT scans using DS and FAS models at 
P21 were performed. Using nine corresponding craniofacial dimensions from 
previous studies (ANTHONY et al. 2010a; RICHTSMEIER et al. 2000), we confirmed 
at P21, these craniofacial characteristics are similarly abnormal in DS and FAS 
mouse models at P21. Nine measurements including minimal frontal breadth, 
inner orbital width, facial depth, nasal length, and bitragal width were all chosen 
as representations of phenotypes observed in humans with DS and FAS (Figure 
1). These skeletal differences show deficits in cranial size, eye size and 
separation, as well as flattening of the face that leads to secondary traits such as 
breathing and feeding problems (RESTA et al. 2003; SPENDER et al. 1996).  
 
3.2 Altered Dyrk1a and Rcan1 expression in DS and FAS embryos 
 The BA1 is the developmental precursor to the mid and lower face which 
includes the mandible and maxillary region. This area includes many of the 
craniofacial abnormalities observed, including a reduced mandible, in both DS 
and FAS. Dyrk1a and Rcan1, genes triplicated in both humans with DS and 
Ts65Dn mice, are thought to be partially responsible for numerous traits in DS 
including neurological deficits as well as craniofacial and bone abnormalities 
(ARRON et al. 2006; DEITZ and ROPER 2011; PARK et al. 2009b). With Dyrk1a and 
Rcan1 dysregulation found in DS models, both in development and in adults, we 
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hypothesized that there would also be a dysregulation of these cardinal genes in 
FAS embryos. 
 Testing three different tissues, BA1, head, and the remainder of the body, 
we observed many irregularities. The BA1, being the most specific structure we 
tested, displayed the most consistent similarities between DS and FAS and had 
significant fold changes of Dyrk1a. In Ts65Dn at E10, Dyrk1a expression was 
significantly decreased by 0.644 fold average as compared to euploid littermates. 
This was similar to our findings in FAS where Dyrk1a expression was decreased 
by 0.701 fold change (Figure 2). Rcan1 in our DS and FAS models were both 
upregulated. Ts65Dn displayed a fold change increase of 1.26, while the ethanol 
treated embryos had a fold change increase of 1.96 (Figure 3). 
Performing qPCR analysis on the head of DS and FAS mouse models also 
displayed dysregulation of these key genes, however, they were not similar in 
expression. Ts65Dn head exhibited a decreased expression of Dyrk1a (0.605) 
while displaying and increase of Rcan1 (1.244) as compared to euploid 
littermates. The ethanol treated FAS model had a small increase of Dyrk1a 
(1.098) and a decreased expression of Rcan1 (0.807). Within the bodies of DS 
and FAS mice differences in expression were also present. Dyrk1a had a fold 
change decrease of 0.675 in Ts65Dn while displayed no significant change in 
Rcan1 expression. The ethanol treated embryos presented an increased fold 
change of Dyrk1a (1.377) and a small increase of Rcan1 (1.126) (Table 2).  
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3.3 Analysis of apoptosis using c-Caspase 3 in the BA1 and the brain 
Ethanol induced apoptosis has been studied extensively in FAS as a 
cause of craniofacial and neurological phenotypes (CARTWRIGHT and SMITH 1995; 
SU et al. 2001; SULIK 2005). For this reason, to fully understand the comparison 
between DS and FAS, we examined apoptotic patterning at a similar 
developmental stage. Embryos of both models were taken at approximately E10 
and somite matched at approximately 24-28 somites. Cells undergoing apoptosis 
in these embryos were observed through immunohistochemistry using an 
antibody for cleaved caspase 3 (c-caspase 3). The patterning that resulted 
displayed expression of the activated caspase 3 in both control and trisomic 
embryos within the BA1 and three regions of the brain; the forebrain, midbrain, 
and hindbrain (Figure 4). These regions of the embryos were quantified carefully 
by counting the amount of cells with caspase 3 expression present. The resulting 
numbers were expressed as a ratio of c-caspase 3 cells in trisomic tissue versus 
euploid tissue. The four trisomic regions, the BA1, forebrain, midbrain, and 
hindbrain, contained increases of 2.36:1, 2.67:1, 1.51:1, and 1.20:1 respectively 
(Table 3). FAS embryo models also contained increases within the BA1, 
forebrain, midbrain, and hindbrain of 5.47:1, 3.29:1, 2.52:1, and 1.59:1 
respectively. The FAS models have a more significant increase, however both 
models to present a modest increase in apoptosis compared to their respective 
controls. 
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3.4 Increased expression of Ttc3 causes a decrease in pAkt 
 To test our hypothesis that Ttc3 is in fact overexpressed and pAkt levels 
are decreased in vivo within craniofacial precursors, we used Ts65Dn E9.5-
E10.5 head, neural tube (NT), and BA1. Performing qPCR using Ttc3 probes, the 
expression levels were tested in the three tissues. It was observed that in the 
head, E10.5 Ts65Dn heads displayed a 1.486 fold change when compared to 
control heads. In E9.5 Ts65Dn embryos, the NT and BA1 displayed an increase 
of 1.443 and 1.413 respectively compared to control embryos (Figure 5). These 
fold changes were theoretically expected due to the trisomic nature of Ttc3. 
 Knowing that our DS mice models contained an increased expression of 
the pAkt E3 ligase in development, we used immunofluorescence to test the 
levels of pAkt in the BA1. Embryos were taken at E9.5 and sectioned. After 
staining, sections were matched as closely as possible to ensure similar tissue 
sections were compared. Through initial qualitative analysis, it was observed that 
within the nucleus there was a much higher expression of pAkt in control sections 
when compared to our trisomic embryos (Figure 6, 7). It was also observed that 
the number of cells in the trisomic BA1 was decreased and that there seems to 
be a lack of organization of those cells.  
  The intensity of the localization of pAkt in the nucleus was quantified 
using ImageJ. Testing sections of seven embryos, four trisomic and three 
euploid, the fluorescence percentage for pAkt in the nucleus at 80X was 
determined. It was found that the percent fluorescence of pAkt in trisomic nuclei 
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was approximately 24.435% with 57.324% fluorescence found in euploid nuclei 
(Figure 8). This quantification supports the qualitative analysis by showing a 
significant increase in percent of pAkt in control BA1 nuclei in vivo compared to 
trisomic BA1 nuclei. 
 
3.5 β5t and β6 protein levels in Ts65Dn thymus 
 Immunodeficiency in DS mouse models may be caused by a 
dysregulation of the assembly of the 20S proteasome in the thymus. This 
dysregulation irregularity may be caused by the proteasome assembly 
chaperone, Psmg1 (Dscr2), which is triplicated in both Ts65Dn and in humans 
with DS. To observe this this potential aberration of 20S proteasome assembly, 
the thymus and brains of trisomic and euploid mice of similar ages, 8-12 weeks, 
were extracted for protein isolation. With the protein isolated, western blots were 
performed using β5t and β6 antibodies to observe any differences. β6, and more 
importantly β5t, are subunits integral in the structure of the thymoproteasome. 
We performed western blots on tissue from the Ts65Dn thymus to indicate any 
irregularities in the thymoproteasome as a potential cause of immunodeficiency 
as well as on the brain which served as control tissue. Our results show that 
while there is a small difference in protein levels of both processed and precursor 
β5t and β6 subunits, that these levels were likely not significant enough to cause 
the immunodeficiency observed in our DS mice (Figure 9).
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CHAPTER 4: DISCUSSION 
 
4.1 DS and FAS Craniofacial Analysis 
 Our first observation that individuals with DS and FAS had similar facial 
features led us to examine previous anthropometric literature. Traits such as 
reduced mandible, overall midface hypoplasia, and almond shaped eyes are 
among those distinct in individuals with and mouse models of DS (ALLANSON et 
al. 1993; RICHTSMEIER et al. 2000). Similar studies of craniofacial traits in 
individuals and mouse models of FAS displayed many of the same craniofacial 
abnormalities (ANTHONY et al. 2010a; MOORE et al. 2002; MOORE et al. 2007). Our 
hypothesis that these two syndromes are similar is based upon the cells that 
create and develop many of these craniofacial traits originate from the same 
region, the neural crest.  
 While these studies were important for the initial investigation of the 
comparison between DS and FAS, it was necessary to compare both our 
respective mouse models at similar developmental ages to ensure no bias. 
MicroCT analysis of both models at P21 demonstrated and confirmed similar 
craniofacial deficits as seen in humans. Furthermore, the minimal frontal breadth 
that was observed to be dissimilar in previous DS and FAS studies was found to 
present the similar deficit in our models. This discrepancy is most likely caused
38 
 
by the difference in the age of the mice that was originally measured in the 
previous studies. This was certainly corrected by the comparison at a similar 
developmental age. 
 While the genetic background of these two mouse models may be 
fundamentally different, we feel that it only supports our hypothesis that two 
different syndromes can present similar phenotypes that occur through similar 
cellular and molecular pathways. Ts65Dn, with the specific background of 
B6(R26R)C3F1 and Ts65Dn, have been used for years as one of the standards 
in DS studies. It is this background that makes this mouse model the one that 
most closely emulates phenotypes that are seen in humans with DS. FAS 
investigators also have several genetic backgrounds of mice that serve as good 
models, however, the model C57BL/6 is one that freely consumes alcohol while 
also presenting many of the same physical and cognitive traits as humans with 
FAS. As we and previous studies have shown, DS and FAS display extremely 
similar morphological traits not only in their respective mouse models, but also in 
humans. 
 
4.2 Cardinal Genes Dyrk1a and Rcan1 
 Dyrk1a and Rcan1 have both been integral in understanding many of the 
phenotypes associated with DS. These two genes are closely tied to phenotypes 
ranging from craniofacial deficits to the occurrence of early onset Alzheimer 
disease. Both Dyrk1a and Rcan1 are able to regulate specific proteins and 
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transcription factors such as Nfat and CREB making the dysregulation of these 
genes detrimental (KIM and SEO 2011; PARK et al. 2009a). Rcan1 has also been 
studied in more specific mechanisms such as its effects on apoptosis in DS 
brains via caspase 9 and caspase 3 activation. Dyrk1a has displayed many 
cellular roles such as development of the brain, effects on cell survival, 
craniofacial abnormalities. For these reasons, it was important to examine the 
expression of these key genes in and FAS system model. 
 Our qPCR analysis of Dyrk1a and Rcan1 exhibited a dysregulation in all 
three tissues; BA1, head, and body, in both Ts65Dn and ethanol treated embryos 
at E10.5. Similarities in genetic expression within the BA1 of both of our DS and 
FAS models were the most significant with its role in craniofacial development. At 
this developmental age, Dyrk1a was decreased similarly and Rcan1 was 
increased in both DS and FAS models. In the head and the body, both of these 
genes were dysregulated but differently from one another. One explanation of 
this anomaly is that the tissue encompassed too general of an area. The BA1 is a 
specific structure with a smaller population of cells that are derived from the 
same source, whereas the head and the body are derived from several different 
populations of cells.  
 Dyrk1a and Rcan1, two genes that are integral in development, are 
dysregulated in both DS and FAS mouse models. Many investigators 
hypothesize that these two genes are possibly dysregulated in DS due to their 
triplication in DS models, but for the first time we have shown that prenatal 
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exposure to ethanol has an effect on their expression. This dysregulation of 
Dyrk1a and Rcan1 can help explain the similarities in craniofacial and cognitive 
phenotypes in both DS and FAS and may provide future targets for the treatment 
of these two syndromes. 
 
4.3 Occurrence of Apoptosis in DS and FAS 
 An increased incidence of cell death that occurs naturally in development 
has been well documented in FAS. It has been previously reported that prenatal 
exposure to alcohol causes apoptosis in NC derived tissues such as the BA1 as 
well as the brain and cranial nerves (DUNTY et al. 2002; WANG and BIEBERICH 
2010). In Ts65Dn, it has been observed that there is a proliferation and migration 
deficit in the NC (ROPER et al. 2009). We aimed to show that not only are there 
proliferation and migration deficits in Ts65Dn, but there is also an overabundance 
of apoptosis in tissue critical for development, similar to observations in FAS 
models. Here we show that in the Ts65Dn BA1 that there is over two-fold more c-
caspase 3 expression than in the controls. This cleaved form of caspase 3, 
known as an excecutioner caspase, is present when there is apoptosis occurring 
in cells. This two-fold increase is similar to ethanol treated embryos that 
displayed an approximately five-fold increase in the same tissue. It is important to 
note that while there was a much higher level of apoptosis occurring within the 
ethanol treated embryos, possibly from the culturing methods itself, it was still 
greater than the cultured controls they were compared to.  
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 In the brain, there is approximately 1.5-2 fold increase of c-caspase 3 in 
the frontal, mid, and hindbrain of the Ts65Dn embryos. This data shows that an 
increase in normal apoptosis may be a cause of cognitive impairment we 
observe in individuals with DS. It has been previously described that apoptosis is 
present in human neural progenitor cells found in ventricular and subventricular 
zones of the cortex and in the frontal cortex of early postnatal Ts65Dn mice (LU 
et al. 2011). Our data, however, for the first time shows an increase of apoptosis 
occurs early in development in Ts65Dn. This deficit found in our DS model 
emulates the apoptotic patterning found in ethanol treated embryos (CHEN et al. 
2011; SARI 2009).  
 While proliferation and migration deficits are seen within the NC of 
Ts65Dn, it is important to show that an overabundance of apoptosis the DS 
mouse model may also cause abnormalities. Both DS and FAS models have now 
been shown to present above normal apoptotic expression during development 
not only in the brain, but also in the BA1 which is attributed to craniofacial 
precursors. Along with the genetic expression of Dyrk1a and Rcan1, similar 
aberrant expression of apoptosis in development is an important step in 
comparing the distinct phenotypes we observe in both DS and FAS mouse 
models. 
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4.4 pAkt expression in Ts65Dn 
 A previous study observed that an E3 ligase, Ttc3, effectively degrades 
the protein Akt while in its active form in the nucleus. This pAkt mechanism 
regulates transcription factors such as CREB and Foxos, having effects on cell 
survival, proliferation, and differentiation. It also has been shown to affect other 
proteins such as transcriptional coactivatior p300, thus affecting the 
transcriptional potential of many genes (HUANG and CHEN 2005). Ttc3 is 
triplicated both in Ts65Dn and in humans. We have shown here that the genetic 
expression at E9.5-E10.5 in Ts65Dn BA1, NT, and head is in fact increased 
approximately 1.5 times euploid levels. With an increased expression of Ttc3 
found in Ts65Dn and its potential effect on pAkt levels, we investigated and 
observed a decrease in pAkt within the nucleus of cells located in the BA1.  
 An increase of the oncoprotein Akt has been shown to induce overgrowth 
in craniofacial, brain, and other tissues as observed in Proteus syndrome where 
this overgrowth is a major phenotype (LINDHURST et al. 2011). Our hypothesis 
states that a decrease of pAkt would hinder growth and decrease cell survival 
within the craniofacial precursors in Ts65Dn embryos. While further studies must 
be shown to investigate the actual effects of pAkt on cells in the BA1, the 
observed decrease of pAkt is a positive step in explaining some of the deficits in 
the BA1 at E9.5-E10.5. 
 The decreased pAkt seen in Ts65Dn also corresponds to an Akt deficit 
seen in FAS rat models caused by an increase in the phosphatase PTEN (GREEN 
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et al. 2007; XU et al. 2003). While the origin of the observed deficit of activated 
Akt in DS and FAS is dissimilar, the outcome is the same. This phenomenon also 
explains the increase in apoptosis that we observe in both models with one of 
Akt’s primary roles being cell survival. 
 
4.5 Immunodeficiency in DS 
 Over several decades, the origin of the immunodeficiency in DS has been 
examined. Several distinct illnesses such as coeliac disease and lymphoblastic 
leukemia have an increased presence in those with DS. Many of these illnesses 
are secondary in nature occurring from structural abnormalities such as heart 
and gastrointestinal defects. Even with the cause of some of these illnesses 
being caused by structural deficits, the underlying problem is located within the 
immune system.  
A gene, Psmg1 (Dscr2), is triplicated in individuals with DS and is 
responsible for aiding the assembly of proteasomes. The potential dysregulation 
of the proteasome machinery presents a major problem in the immune system. 
Psmg1 plays a role in processing subunits that make up the proteasome. The 
subunits that are processed irregularly may cause a deficient immune system. To 
observe this, we investigated the processed levels of the β5t subunit, a major 
part of the 20S thymoproteasome. Observing the levels of both the precursor and 
processed β5t protein within the thymus of Ts65Dn, we found no significant 
difference compared to euploid mice. Although the gene responsible for the 
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assembly of the 20S proteasome contains three copies, it seems to have no 
effect on this facet of the immune system. 
 Many new studies on immunodeficiency in DS have focused on other 
factors within the immune system such as decreased naïve T cell numbers. 
Naïve T cells are an important part of the immune system, playing a role in 
identifying newly acquired pathogens that have not been present before. A recent 
study has shown that the low numbers of these T cells is caused by a decreased 
thymic output (BLOEMERS et al. 2011). While more studies have focused on the 
decreased levels of naïve T cells and overall thymic output, for the first time we 
report that there is no significant complication with proteasome assembly that 
would support the observed immunodeficiency in DS. 
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TABLES 
 
 
 
 
Table 1 Phenotypic Analysis of DS and FAS: A review of over 15 studies investigating craniofacial, structural, and 
cognitive traits in both humans and mouse models of DS and FAS. All studies show significant similarities between DS 
and FAS except one, the minimal front breadth in the mouse models 
 Human Mouse 
 Traits DS FAS DS FAS 
C
ra
n
io
fa
c
ia
l 
A
n
th
ro
p
o
m
e
tr
y
 
Minimal Front Breadth Smaller
(ALLANSON et al. 1993; FARKAS et al. 2001)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 Larger
(RICHTSMEIER et al. 2000)
 Smaller
(ANTHONY et al. 2010a)
 
Skull Base Breadth Smaller
(ALLANSON et al. 1993; FARKAS et al. 2001)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 Smaller
(RICHTSMEIER et al. 2000)
 Smaller
(ANTHONY et al. 2010b)
 
Upper & Lower Facial 
Width 
Smaller
(ALLANSON et al. 1993; FARKAS et al. 2001)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 Smaller Smaller
(ANTHONY et al. 2010b)
 
Canthal Distances Smaller
(ALLANSON et al. 1993)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 Smaller
(RICHTSMEIER et al. 2000)
 Smaller
(ANTHONY et al. 2010b)
 
Palpebral Fissure Smaller
(FARKAS et al. 2001)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 N/A Smaller
(ANTHONY et al. 2010b)
 
Nasal Smaller
(ALLANSON et al. 1993; FARKAS et al. 2001; FERRARIO et 
al. 2004)
 
Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 Smaller
(RICHTSMEIER et al. 2000)
 Smaller
(ANTHONY et al. 2010b)
 
Philtrum Length Smaller
(FARKAS et al. 2001; FERRARIO et al. 2004)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 N/A Larger
(ANTHONY et al. 2010b)
 
Facial Height Smaller
(ALLANSON et al. 1993; FARKAS et al. 2001)
 Smaller
(MOORE et al. 2007)
 N/A Smaller  
Facial Depth Smaller
(ALLANSON et al. 1993)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 N/A Smaller
(ANTHONY et al. 2010b)
 
Maxillary & Mandibular 
Arc 
Smaller
(ALLANSON et al. 1993)
 Smaller
(MOORE et al. 2002; MOORE et al. 2007)
 Smaller* N/A 
Head Circumfrence Smaller
(ALLANSON et al. 1993)
 Smaller
(MOORE et al. 2002)
 Smaller* Smaller* 
B
ra
in
 
Microcephaly Present
(MOLLER et al. 2008)
 Present
(ELLIOTT et al. 2008)
 Present
(HAYDAR et al. 2000)
 Present
(O'LEARY-MOORE et al. 2010)
 
Cerebellum Reduced
(FIDLER and NADEL 2007)
 Reduced
(NORMAN et al. 2009)
 Purkinje Cells
(LOMOIO et al. 2009)
 Purkinje cells
(CEBOLLA et al. 2009; 
SERVAIS et al. 2007)
 
Hippocampus Reduced
(FIDLER and NADEL 2007)
 Reduced
(NORMAN et al. 2009)
 Dentate Gyrus
(BIANCHI et al. 2010)
 Dentate Gyrus
(ROBERSON et al. 
2009)
 
Cortex Neuronal Impairment
(UNTERBERGER et al. 2003)
 Neuronal Impairment
(FERRER and GALOFRE 
1987; MEINTJES et al. 2010)
 
Neuronal Impairment
(CHAKRABARTI et al. 2007)
 Neuronal Impairment
(INCERTI 
et al. 2010)
 
Learning Impaired
(FIDLER and NADEL 2007)
 Impaired
(CALEY et al. 2005; STREISSGUTH et al. 
2004)
 
 Impaired
(KURT et al. 2000)
 Impaired
(IERACI and HERRERA 2007)
 
Memory Impaired
(FIDLER and NADEL 2007)
 Impaired
(COLES et al. 2010)
 Impaired
(KURT et al. 2000)
 Impaired
(IERACI and HERRERA 2007)
 
O
th
e
r 
o
rg
a
n
/ 
s
tr
u
c
tu
re
 
Heart Septal
(WEIJERMAN et al. 2010)
 Septal
(BURD et al. 2007)
 Septal
(WILLIAMS et al. 2008)
 N/A 
Bone Development Reduced
(GONZALEZ-AGUERO et al. 2011)
 Reduced
(SNOW and KEIVER 2007)
 Reduced
(BLAZEK et al. 2010)
 N/A 
Stature Short
(MYRELID et al. 2002)
 Short
(SPOHR et al. 2007)
 Short
(BLAZEK et al. 2010)
 N/A 
Limbs Malformed
(GUPTA et al. 2001)
 N/A N/A Malformed
(CHEN et al. 2004)
 
Hearing Loss
(HANS et al. 2010)
 Loss
(KVIGNE et al. 2004)
 Loss
(HAN et al. 2009)
 N/A 
Kidney Displasia
(KUPFERMAN et al. 2009)
 Displasia
(HOFER and BURD 2009)
 N/A N/A 
GI tract Pseudoobstruction
(AWAN et al. 2004a)
 Pseudoobstruction
(HOFER and BURD 2009)
 N/A N/A 
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Table 2 Dyrk1a and Rcan1 Expression: Summary of qPCR analysis of both 
Dyrk1a and Rcan1 expression in both DS and FAS mouse models. Note that the 
fold changes of these two cardinal genes are similarly expressed in the BA1 
 
  
Ts65Dn 
Dyrk1a 
Ethanol 
Dyrk1a 
Ts65Dn 
Rcan1 
Ethanol 
Rcan1 
BA
1 0.644 0.701 1.255 1.963 
H
ea
d 0.605 1.098 1.245 0.807 
Bo
dy
 
0.675 1.377 1.015 1.126 
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Table 3 c-Caspase Expression: Ratio of apoptotic expression was analyzed in a 
previous study of ethanol treated embryos (CHEN et al. 2011) and was compared 
to Ts65Dn. The ratios both display significant increases when compared to their 
respective controls. Both models embryos were selected for similar somite age 
(24-28). Ts65Dn n=3, Ethanol treated n=4 
Tissue Ratio Trisomic:Euploid Ratio Ethanol:Control 
First Branchial Arch 2.63:1 5.47:1 
Forebrain 2.67:1 3.29:1 
Midbrain 1.51:1 2.52:1 
Hindbrain 1.20:1 1.59:1 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIGURES 
 
 
 
 
 
 
 
 
 Figure 1 MicroCT analysis: These measurements are taken from Ts65Dn(+) and ethanol treated mice at P21. They are 
compared to controls of both models, Ts65Dn(-) and untreated C57BL/6 mice. The nine measurements are to show 
similar craniofacial abnormalities as seen in humans with DS and FAS 
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Figure 2 Dyrk1a Expression in DS and FAS Mouse Models: The qPCR analysis 
of Dyrk1a in Ts65Dn and ethanol treated embryos at E10 display dysregulation 
throughout. The BA1 however presents similar expression which is relevant to 
craniofacial deficits. Ts65Dn displays a more consistent expression throughout 
the tissues. The ethanol treated embryos present a less consistent expression 
having decreased expression in the BA1, slightly normal expression in the head, 
and over expression in the body. The error bars represent a standard error. All 
tissues from both DS and FAS models contained sample sizes of 5 
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Figure 3 Rcan1 Expression in DS and FAS Mouse Models: qPCR analysis of 
Rcan1, like Dyrk1a, also displays dysregulation throughout the embryo at E10 in 
both DS and FAS models. There is a similar increase in expression in the BA1, 
once again showing possible origins of similar craniofacial deficits. Error bars 
represent standard error. All tissues and models contain a sample size of 5 
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Figure 4 Immunohistochemistry analysis using Caspase 3: Two embryos, 
Trisomic (L) and Euploid (R), were stained for c-Caspase 3. A total of 3 
comparisons, 3 trisomic and 3 euploid, were carried out. Arrows in this 
representation point to areas of significance including the BA1 and the midbrain 
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Figure 5 Ttc3 Expression in Ts65Dn: Ttc3 expression in three different tissues of 
Ts65Dn mice were analyzed using qPCR . All three tissues display an increase 
of approximately 1.5 fold over control embryos. Sample size for the head, NT, 
and BA1 is n=6, 4, and 5 respectively 
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Figure 6 40X immunofluorescence of pAkt in the BA1 of Ts65Dn: In A and B is 
normal euploid expression of activated Akt. Red stain is pAkt, blue is DAPI 
nuclear staining, and green is the localization of both DAPI and pAkt showing 
activity in the nucleus. In C and D, Trisomic BA1s were stained and analyzed in 
the same fashion. There is a significant amount more of nuclear pAkt in euploid 
BA1 when compared to trisomic BA1. Arrows label cells within the BA1 that are 
indicative of the results found. Note that the euploid cells (A, B) contain much 
more pAkt within the nucleus than the trisomic cells (C, D) and that the 
organization and number of trisomic cells is much less 
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Figure 7 80x Immunofluorescence of pAkt in the BA1 in Ts65Dn: A closer view of 
euploid (A, B) and trisomic (C, D) cells show the difference more clearly 
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Figure 8 Immunofluorescence Analysis of pAkt expression in the nucleus: The 
quantification of overall percent of pAkt fluorescence in trisomic and euploid BA1 
nuclei. Error bars indicate standard error. Sample size for euploid analysis was 3 
different embryos and 14 sections. Trisomic analysis contained 4 total embryos 
and 13 sections. Fluorescence was analyzed using ImageJ 
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Figure 9 Proteasome Subunit Analysis on Ts65Dn Thymic Tissue: Western blot 
of proteins isolated from Ts65Dn trisomic and euploid thymus and brain. β5t and 
β6 showed no significant difference in expression between trisomic and euploid 
thymus. Ts65Dn(-) was used as both positive and negative control with β5t 
having no expression in the brain and β6 having a decreased expression 
compared to thymic tissue 
 
 
 
 
 
 
